

Applicants : SHEN, et al.  
U.S. Serial No.: 10/032,514  
Filed : October 24, 2001  
Page : 2

Amendments to the Claims:

1.-43. (Canceled)

1/ 44. (Currently amended) A composition comprising a supercritical extract[[s]] of *Flos Lonicerae* and *Fructus Forsythiae*, an aqueous extract [[from]] of *Flos Lonicerae* and *Fructus Forsythiae*, aqueous extract of *Radix Scutellariae*, and a suitable carrier.

2/ 45. (Currently amended) An antiviral, antibacterial, anti-anaphylaxis, anti-inflammatory or antifebrile pharmaceutical composition comprising the composition of claim ~~[[1]]44~~ and ~~*Radix Scutellariae* and a pharmaceutically acceptable carrier.~~

3/ 46. (Presently presented) A composition of claim ~~[[1]]44~~, wherein the ratio of ingredients <sup>for</sup> *Flos Lonicerae*, *Fructus Forsythiae* and *Radix Scutellariae* is approximately 1:2:1.

4/ 47. (Currently amended) A composition of claim ~~[[1]]44~~, comprising about 90-180 parts of aqueous extract of *Flos Lonicerae* and *Fructus Forsythiae*, about 10-60 parts of supercritical carbon dioxide (CO<sub>2</sub>) extract of *Flos Lonicerae* and *Fructus Forsythiae*, about 30-50 parts of aqueous extract of *Radix Scutellariae* and 23-125 parts of <sup>a suitable carrier</sup> ~~excipients.~~

5/ 48. (Currently amended) A composition of claim ~~47~~ comprising about 0.01 percent to about 99.99 percent of effective ~~extract~~ <sup>a suitable carrier</sup> ~~or combination of extracts~~, and about 99.99 percent to 0.01 percent of ~~medical recipients.~~

6/ 49. (Currently amended) A composition of claim ~~47~~, wherein said ~~extract or combination of extracts~~ <sup>present</sup> ~~are~~ <sup>presented</sup> in the following formula: about 10 percent to 100 percent *Flos*

Applicants : SHEN, et al.  
U.S. Serial No.: 10/032,514  
Filed : October 24, 2001  
Page : 3

Lonicerae, about 10 percent to 100 percent *Fructus Forsythiae*  
and about 10 percent to 100 percent *Radix Scutellariae*.

7 <sup>4</sup> 50. (Currently amended) A composition as in claim 42, further comprising about 1.3 percent to 1.6 percent of chlorogenic acid, 0.2 percent to 0.3 percent of phillyrin and about 14.1 percent to 15.3 percent of [[B]]baicalin.

8 <sup>2</sup> 51. (Currently amended) The composition of claim 45, wherein said ~~extract or~~ combination of extracts has antiviral activity against [[h]]Herpes I virus and [[h]]Herpes II virus.

9 <sup>2</sup> 52. (Currently amended) An antibacterial composition of claim 45, wherein said ~~extract or~~ combination of extracts has antibacterial activity against *Bacillus cereus*, [[s]]*Shigella shigae* and ~~*Bacillus coli*~~ *Escherichia coli*.

10 <sup>2</sup> 53. (Currently amended) An anti-anaphylaxis composition of claim 45, wherein said ~~extract or~~ combination of extracts can inhibit ileum contraction induced by histamine.

11 <sup>2</sup> 54. (Currently amended) An anti-inflammatory composition of claim 45, wherein said ~~extract or~~ combination of extracts can inhibit leukotaxis, xylene-induced inflammation and albumen-induced inflammation.

12 <sup>2</sup> 55. (Currently amended) An antifebrile composition of claim 45, wherein said ~~extract or~~ combination of extracts can inhibit typhoparatyphoid A and B-induced pyrexia.

Applicants have amended the claims according to the Examiner's suggestions. Applicants believe that the amended claims should obviate this ground of rejection.